U.S. Tariffs on India’s pharma: Who pays, what’s at risk Vivek Seigell, Sr VP, Corporate Affairs, Apeejay Stya Svran Group Aug 12, 2025 The structural answer to tariff risk is not endless cost-cutting; it is moving up the value chain
